New
BC10+TB10+GHK50 (Glow)
119,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Comprehensive tissue regeneration in the musculoskeletal and integumentary systems.
- GHK-Cu provides systemic anti-aging benefits and supports skin and hair health.
- Improved synthesis of collagen and the extracellular matrix.
- Systemic antioxidant and anti-inflammatory protection.
- Premium full-body restoration protocol with aesthetic and functional benefits.
Description
BPC 10 mg + TB 10 mg + GHK-Cu 50 mg (Glow Combination)
Regeneration / Anti-Aging Stack
MECHANISM OF ACTION
Triple-peptide synergy: BPC-157 promotes VEGF-mediated tissue repair, TB-500 promotes systemic cell migration and differentiation, and GHK-Cu activates more than 4,000 genes involved in anti-aging, collagen synthesis, the antioxidant response, and immune modulation.
KEY BENEFITS
- Comprehensive tissue regeneration in the musculoskeletal and integumentary systems.
- GHK-Cu provides systemic anti-aging benefits and supports skin and hair health.
- Improved synthesis of collagen and the extracellular matrix.
- Systemic antioxidant and anti-inflammatory protection.
- Premium full-body restoration protocol with aesthetic and functional benefits.
SIDE EFFECTS AND SAFETY
All three components have excellent safety profiles. The addition of GHK-Cu does not introduce any new risks at therapeutic doses.
RESEARCH AND CLINICAL NOTES
According to Pickart et al., GHK-Cu modulates the expression of genes involved in anti-aging and inflammation. This combination positions this product as a premium longevity intervention.
TARGET PROFILE:
Protocols for longevity, well-being, anti-aging medical practices, and biohacking.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
CJC-1295 without DAC
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
Ipamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A clean GH surge with no side effects associated with cortisol or prolactin.
- Increased lean muscle mass and fat loss.
- Improved sleep quality and recovery.
- Regulation of intestinal motility, with application in ileus.
- Ideal for long-term use due to its selectivity profile.
- Reference for use in combination with CJC-1295 without DAC.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
New
Tesamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH's natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
